Russia’s mad rush for vaccine alarming West
COVID-19 cases worldwide
MOSCOW — Russia boasts that it’s about to become the first country to approve a COVID-19 vaccine, with mass vaccinations planned as early as October using shots that are yet to complete clinical trials — and scientists worldwide are sounding the alarm that the headlong rush could backfire.
Moscow sees a Sputniklike propaganda victory, recalling the Soviet Union’s launch of the world’s first satellite in 1957. But the experimental COVID-19 shots began first in-human testing on a few dozen people less than t wo months ago, and there’s no published scientific evidence yet backing Russia’s late entry to the global vaccine race.
“I’m worried that Russia is cutting corners so that the vaccine that will come out may be not just ineffective, but also unsafe,” said Lawrence Gostin, a global public health law expert at Georgetown University. “It doesn’t work that way. Trials come first. That’s really important.”
According t o Ki r i l l Dmitriev, head of Russia’s Direct Investment Fund that bankrolled the effort, a vaccine developed by the Gamaleya research institute in Moscow may be approved within days before scientists complete what’s called a Phase 3 study. That final-stage study, usually involving tens of thousands of people, is the only way to prove if an experimental vaccine is safe and works.
Health Minister Mikhail Murashko said members of “risk groups,” such as medical workers, may be offered the vaccine this month. He didn’t clarify whether they would be part of the Phase 3 study said to be completed after the vaccine receives “conditional approval.”
Deputy Prime Minister Tatyana Golikova promised to start “industrial production” in September, and Murashko said mass vaccination may begin as early as
October.
Dr. Anthony Fauci, the top U.S. infectious disease specialist, questioned the fast-track approach last month. “I do hope that the Chinese and the Russians are actually testing a vaccine before they are administering the vaccine to anyone, because claims of having a vaccine ready to distribute before you do testing, I think, is problematic at best,” he said.
Questions about this vaccine candidate come after the U.S., Britain and Canada in July accused Russia of using hackers to steal vaccine research from Western labs.
Delivering a vaccine first is a matter of national prestige for the Kremlin as it tries to assert the image of Russia as a global power capable of competing with the U.S. and China. The notion of being “the first in the world” dominated state news coverage of the effort.
In April, President Vladimir Putin ordered state officials to shorten the time of clinical trials for a variety of drugs, including potential coronavirus vaccines.
According to Russia’s Association of Clinical Trials Organizations, the order set “an unattainable bar” for scientists who, as a result, “joined in on the mad race, hoping to please those at power.”
The association first raised concern in late May, when professor Alexander Gintsburg, head of the Gamaleya institute, said he and other researchers tried the vaccine on themselves.
The move was a “crude violation of the very foundations of clinical research,
Russian law and universally accepted international regulations,” the group said in an open letter to the government, urging scientists and health officials to adhere to clinical research standards.
But a month later, the Health Ministry authorized clinical trials of the Gamaleya product with what appeared to be another ethical issue.
Human studies started June 17 among 76 volunteers. Half were injected with a vaccine in liquid form and the other half with a vaccine that came as soluble powder. Some in the first half were recruited from the military, which raised concerns that servicemen may have been pressured to participate.
Some experts said their desire to perform well would affect the findings. “It’s no coincidence media reports we see about the trials among the military said no one had any side effects, while the (other group) reported some,” said Vasily Vlassov, a public health ex p e r t with Moscow’s Higher School of Economics.
As the trials were declared completed and looming regulatory approval was announced last month, questions arose about the vaccine’s safety and effectiveness. Government assurances the drug produced the desired immune response and caused no significant side effects were hardly convincing without published scientific data describing the findings.
The World Health Organization said all vaccine candidates should go through full stages of testing before being rolled out. “There are established practices and there are guidelines out,” WHO spokesman Christian Lindmeier said last week. “Between finding or having a clue of maybe having a vaccine that works, and having gone through all the stages, is a big difference.”
Offering an unsafe compound to medical workers on the front lines of the outbreak could make things worse, Georgetown’s Gostin said.
Vaccines that are not properly tested can cause harm in many ways — from a negative impact on health to creating a false sense of security or undermining trust in vaccinations, said Thomas Bollyky, director of the global health program at the Council on Foreign Relations.
“It takes several years to develop any drug,” said Svetlana Zavidova, executive director of Russia’s Association of Clinical Trials Organizations. “Selling something the Gamaleya (institute) tested on 76 volunteers during Phase 1-2 trials as a finished product is just not serious.”
The vaccine candidate uses a different virus — the common cold-causing adenovirus — that has been modified to carry genes for the “spike” protein that coats the coronavirus, as a way to prime the body to recognize if a real COVID-19 infection comes along. That’s similar to vaccines being developed by China’s CanSino Biologics and Britain’s Oxford University and AstraZeneca.